Six months ago I wrote up LogiPharma Austria and broke my own format. No top 5. Just one takeaway, because one hit harder than the rest: a large Pharma team sat down with us and said, “Guys, we're confused. Everybody out there is saying they can do the same thing.”
Boston was different.
Nobody told me they were confused this year. Not once…despite every vendor’s marketing teams working overtime to converge on the same ‘visibility is boring, we are AI, we love GxP’ message.
Pharma told me they were being careful. Which is a very different problem, and honestly a much better one.
We ran our masterclass, hosted Cold Chain After Dark 52 floors above the city, and spent three days in back-to-back conversations with customers, prospects, device makers, packagers and 4PLs.
Here are my 9 takeaways.
Let me start with the least technical takeaway, because it mattered the most.
Cold chain is a village.
The person you oversold in 2023 is the person running the evaluation in 2026. The quality lead who left for a competitor still remembers whether your team told them the truth when something broke.
And in a market where every booth says AI, every deck says agentic, and every website says GxP, reputation is the only differentiator that cannot be copied by a marketing team over a weekend.
Trust still takes years to build, and seconds to lose.
The takeaway: the gap between marketing and product capability can survive in unregulated commoditized markets, but becomes painfully obvious in GxP regulated Life Sciences value chain.
In June I wrote about POC purgatory and why technology evaluations in this industry can improve.
Boston confirmed it. And then raised the stakes.
Because now everybody is GxP.
Everybody does quality release. Everybody has validation. Everybody has an audit trail. Everybody's agent is grounded. Everybody's platform is agnostic.
The perception war is fully on, and it is being fought with language, not architecture.
But here is what surprised me.
Pharma is not biting. Every conversation default starts with skepticism until proved otherwise.
In 2023, a good demo and a confident answer could get you into a paid pilot in twelve weeks. In 2026, I watched sophisticated buyers slow walk things that six months ago would have moved. And it wasn't because they weren't interested. But more so because they have scar tissue.
They bought a control tower. They are still paying for it. They have integrations that nobody owns, dashboards nobody opens, and an implementation bill that never quite stopped.
No more tech debt. I heard a version of that phrase from three separate companies in three days.
So the bar moved. It is no longer can you demo it. It is:
For us, slower buying is the best news of the conference.
Because rigorous diligence only hurts you if you were counting on the buyer not looking closely.
This is the takeaway I would have argued against two years ago.
We used to approach every account with a leading value proposition around tech stack consolidation. One platform. One record. Normalize and contextualize disparate data.
That approach ignored some of the great work that a Pharma partner may have invested to date.
Over recent years, PAXAFE has been fortunate to have won greenfield evaluations where a company started from scratch. PAXAFE has also replaced incumbents outright.
But equally important, PAXAFE is now being brought in to sit beside other platforms the customer already bought. And its incumbent on all providers to make that experience as seamless and flexible as possible for each pharma partner.
We now see scenarios where PAXAFE runs cold chain while another platform runs everything that is not cold chain.
Or PAXAFE runs Lane Qualification and Product Release while someone else owns the visibility control tower entirely.
Both of those used to feel ‘incomplete.’ They are not.
The mature play is to be unambiguously the best at a layer, and genuinely interoperable on the rest.
Which, by the way, is a real test of whether your “agnostic” claim means anything. It is easy to be agnostic about devices or packaging. It is much harder to be agnostic about control towers, and to be interoperable enough not owning the visibility layer while still being the system of record for the quality decision.
A rising tide lifts all boats. I said that in April and I meant it.
There is more cold chain software spend coming into this market than any one company is going to absorb.
Two years ago I did not envy the device CEO job. Margins compressing, software companies eating the value layer, customers demanding agnosticism.
Today, I look at it differently.
Because size aside, right now, there is a significant hardware leadership opportunity. And the opening is not where most are looking.
There’s a real opportunity is getting back to the basics:
That’s it – that’s the opportunity. Provide reliable, consistent, cost-effective hardware with great service around it.
Somebody is going to win it by being the one whose data is boringly, relentlessly consistent. Same schema. Same semantics. Documented. Validated. Predictable every time.
Marketing automation, lane risk and prediction is cool – but it has to come after a consistent data feed.
I believe that embracing and owning focus on getting the basics right will actually stand out.
Earlier this year we announced our partnership with Peli BioThermal.
Here is why that matters more than a typical logo exchange.
Packaging is the most under-instrumented input in the entire cold chain. Think about how it actually works today. A packaging or quality engineer qualifies a solution. It gets written into an SOP. A planner picks it off a list. And then it is treated as a static spec sheet for the next three years, while the lanes it runs on change constantly.
Now imagine the loop closes. Qualification informs the pack-out. Actual lane performance informs the next qualification. Excursion behavior on a real route tells you something about the packaging that a chamber study never will. Over-packaging, which is a massive and largely invisible cost in this industry, becomes something you can actually measure your way out of.
That is the direction. There are some genuinely interesting developments here that we look forward to sharing in 2027.
This one is a little self-critical, so bear with me.
Do you know the most common questions PAXAFE’s ATHENA gets asked?
“What's the status of shipment X?”
“How many shipments are at risk right now?”
“Can you pull a list of my shipments into Excel?”
Users download the Excel. And they do the analysis by hand. On questions the agent could have answered in seconds, with evidence, with citations & links back to the source data.
Here is my honest reaction. You do not need AI for any of that. You need good filters.
A status lookup is a search problem. A count is a filter problem. An export is a button.
If your AI strategy is answering questions a well-designed table would have answered, you have bought a very expensive table.
AI earns its keep somewhere else entirely. On the inferential questions. The derivative ones. The ones where something actually has to be weighed:
Those are not lookups. Those are judgments, with weighting, that a human would need days and several spreadsheets to assemble.
So why does nobody ask them?
Because you don't know what you don't know. Nobody shows up to a new tool with their hardest question. They show up with their safest one, confirm it works, and then go back to the workflow they already trust.
That is a product problem and an enablement problem, and it is ours to solve, not the customer's.
This is the takeaway that tells me the market has genuinely matured.
For a decade, visibility was binary. Do you have it, or do you not?
And it got mistaken for a platform functionality rather than a product feature -- I can stream location. I can stream temperature. Therefore I have visibility.
With no consideration of data quality. Or reliability. Or granularity. Or completeness. Or the so what, now what part of the downstream equation.
That is over.
What I heard instead were much better questions:
That last one is the whole ballgame.
Because a shipment ID is a logistics construct. A device ID is a hardware construct. Neither of them is the thing your quality organization actually makes decisions about.
Your quality team releases product. Batches. Handling units. Things that nest inside other things, split across destinations, get repacked, and carry their exposure history with them from one leg to the next.
If your ‘visibility’ can show a beautiful map but still be unable to answer the only question that matters: is this specific pallet releasable…?
…then you may have a nice track & trace feature, but not a visibility platform.
The downstream implications are enormous. Partial release. Quarantine of one unit while the rest moves. Cumulative exposure across legs. Batch lineage. Every one of those is blocked if you got the unit of truth wrong at the ingest layer.
In debriefing with Sahil Sangwan, Head of Data at PAXAFE, his perspective after sitting in on numerous panels and pharma presentations is that everybody claims to be building agents, but no one seems to be measuring impact, ROI and token costs. We project that will become the theme for Logipharma in the next 1-2 years.
In April, the problem was confusion. Everybody said the same words and nobody could tell them apart.
In October, the problem is caution. They can tell the difference now by asking the right questions. They are just not going to be rushed, and they are not willing to take on more tech debt to find out.
I will take caution over confusion every single time.
Confusion rewards whoever markets loudest. Caution rewards whoever built the thing.
So if you are heading into an evaluation in 2027, my advice has not changed much from June. Bring your ugliest files. Ask what year three costs. Ask how the data will flow, and how many systems you’ll need. Ask whether the system tracks your product or just your devices.
And then watch what happens when somebody has to show the work.
See you at LogiConnect!
PAXAFE is a GxP decision intelligence platform that strives to put the end-to-end cold chain on autopilot.
Acting as the system of record for every time, temperature and value sensitive shipment and batch, PAXAFE works with cold chain manufactures and service providers to eliminate silos, ensure compliance, and empower teams with contextual intelligence to maximize patient trust and customer outcomes.
PAXAFE works with large, mid-size and small pharma and biotech enterprises, as well as logistics service providers selling into Life Sciences markets.